Blog

New Strategic Partnership with AstraZeneca

Today we announced a major milestone in the shape of a long-term strategic collaboration with AstraZeneca.

This partnership combines BenevolentAI’s expertise in AI and machine learning to identify novel insights from scientific data with AstraZeneca’s excellence in R&D to identify new targets in two therapeutic areas of huge unmet need: Idiopathic Pulmonary Fibrosis (IPF) and Chronic Kidney Disease (CKD).

The collaboration is important for BenevolentAI as it comes with an upfront payment, development milestone payments and tiered royalties on future revenues.  But, more importantly, the spirit of this deal is different. Rather than a standard service provision agreement, this deal represents a true partnership: combining AstraZeneca’s world-leading disease area expertise and large diverse datasets together with our machine learning discovery and AI-enabled target ID capabilities.

AstraZeneca and BenevolentAI will work side by side in joint multidisciplinary teams, integrating working practices across data science, machine learning, respiratory and cardiovascular R&D, Target ID and precision medicine to break down traditional drug discovery boundaries and enable more efficient data-driven decision making. The combined AstraZeneca/BenevolentAI teams will incorporate proprietary data, tailor approaches to using that data, jointly interpret the results and then work together to identify targets that we hope will lead to new medicines.

Partnerships aren’t forged on paper. In all our interactions to date, AstraZeneca has proven to be open, progressive and committed to working together. Both companies share a common purpose and mindset in unlocking the power of scientific data to make more effective drugs for the people that need them and I’m incredibly excited to combine forces with them on targeting two critical disease areas that affect the lives of millions of people.

Joanna Shields, CEO

More Posts

You Might Also Like

Video
Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022